Geron Corporation Shareholders: Class Action Lawsuit Filed by The Gross Law Firm

The Gross Law Firm's Class Action Notice for Geron Corporation Shareholders

The Gross Law Firm has officially announced the filing of a securities class action suit on behalf of shareholders of Geron Corporation (NASDAQ: GERN). The firm invites those who purchased GERN shares during the class period from February 28, 2024, to February 25, 2025, to consider registering for the class action. This class action is particularly timely as it addresses allegations regarding significant misinformation provided to investors concerning the company's drug, Rytelo (imetelstat).

Background Information

Geron Corporation is renowned for developing innovative therapies aimed at treating chronic and terminal diseases, with Rytelo positioned as a flagship product. However, recent reports have raised serious concerns about the anticipation and growth potential of this drug, leading to a tense atmosphere among its shareholders.

According to the accusations laid out in the complaint, company executives allegedly misled investors about both the demand for Rytelo and the feasibility of meeting projected sales targets. They expressed unwarranted confidence that Geron would successfully capture the market, particularly among patients ineligible for first-line Erythropoiesis-Stimulating Agents (ESAs). These statements neglected to adequately disclose the inherent risks associated with necessary weekly patient monitoring and competitive market pressures that have significantly affected Rytelo's sales performance.

Declining Stock Performance

Things took a dramatic turn on February 26, 2025, when Geron released its fourth quarter financial results for fiscal 2024. The announcement revealed that Rytelo's growth had substantially slowed down, attributing the slowdown to several factors: increased competition, seasonal influences, and a general lack of patient awareness regarding the drug. This fallout led to a startling plummet in Geron's stock value, dropping from $2.37 per share on February 25 to just $1.61 per share on February 26—a staggering decline of approximately 32.07% in one day.

As stakeholders grapple with the backlash of this news, they might face vital decisions moving forward. Shareholders affected by these circumstances are encouraged to register their information with The Gross Law Firm to seek participation in potential recovery actions.

Important Deadlines

The firm has highlighted that the deadline for shareholders to register for participation in this class action is May 12, 2025. Prospective participants can easily register through the provided links, which allow for streamlined submission and management of claims relating to GERN.

Moreover, registering as a shareholder also enrolls individuals in a monitoring program, offering real-time updates throughout the life cycle of the case. Importantly, individuals do not need to serve as lead plaintiffs to be eligible to recover some losses incurred due to the downdraft in the company's stock price.

Why Choose The Gross Law Firm?

The Gross Law Firm is a recognized national entity specializing in class action lawsuits. Their commitment centers on safeguarding investors’ rights amidst unethical business practices. Their mission includes pursuing justice for clients who have endured losses due to corporate misconduct that has artificially inflated stock prices through misleading reports and omissions. The firm emphasizes the importance of corporate accountability and responsible communication with investors.

If you believe you are entitled to compensation for financial losses attributable to Geron Corporation's alleged misconduct, now is the time to act. The Gross Law Firm can provide the legal representation necessary to navigate this complex case and pursue rightful recovery on your behalf.

For those who wish to reach out or require additional information about the class action, you can contact The Gross Law Firm directly:

Address: 15 West 38th Street, 12th floor, New York, NY, 10018

Email: [email protected]
Phone: (646) 453-8903

Conclusion

The upcoming months will be crucial for Geron Corporation shareholders. As the class action unfolds, affected investors will be watching closely to see how justice can be served and losses mitigated in light of recent events. Taking timely action can safeguard one’s rights and the potential for recovery as further developments in the case emerge.